Janssen Propulsid promotions include newsletter given to consumers filling GI prescription.
JANSSEN PROPULSID DIRECT-TO-PATIENT PROMOTION INCLUDES PHARMACY NEWSLETTER provided to people receiving competing products, Janssen Gastroenterology & Mycology Group Director Joseph Sanger told Industry Events International's PharMillenium conference Jan. 29 in Stuart, Fla. When a patient receives a prescription for a product such as Astra Merck's Prilosec, an accompanying newsletter is automatically printed "talking about motility disorders, and that another medication like Propulsid may be more appropriate." The newsletter, "along with the prescription, is given to the patient. Chain pharmacies are selling these programs to us," Sanger said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth